Tumor staging using 3.0 T multiparametric MRI in prostate cancer: impact on treatment decisions for radical radiotherapy

SpringerPlus

Table 5 Clinical studies evaluating the impact of the staging using MRI in PCa patients treated with RT

Study	Type of MRI	n	Field strength	Coil	Tumor stage shift ( %)	Risk group changes ( %)	Change in RT (CTV, doses, HT) ( %)	Technique validation
Panje et al. (2015)	Multiparametric	122	1.5 T & 3 T	PAB	55.7	28.7	30	No
Horsley et al. (2015)	Morphological	509	1.5 T	PAB	20	9	18	No
Yamaguchi et al. (2015)	Morphological	157	1.5 T	PAB	25	9	8^a	No
Couñago et al. (2014)	Multiparametric	103	3 T	PAB	94.1	33.9	33.9	Yes
Chang et al. (2014)	Morphological	115	1.5 T	PAB	68.6	7	20^a	No
Jackson et al. (2005)	Morphological	199	1.5 T	PAB	55	NR	32.6^b	No
Present study	Multiparametric	274	3 T	PAB	90.4	32.8	43.8 or 52.5^c	Yes

Not RT change reported
PAB Phased-array-bodycoil, NR not reported, CTV clinical target volume, HT hormonal therapy
^aExclusive assessment of the CTV change
^bData from T1–T2 to T3–T4 upstaging
^cValues according to the HT criteria in intermediate-risk patients